BTIG Reiterates Buy Rating on Progenics Pharmaceuticals (PGNX)

August 12, 2019 9:29 AM
BTIG analyst Timothy Chiang reiterated a Buy rating and $14.00 price target on Progenics Pharmaceuticals (NASDAQ: PGNX), citing Multiple Upcoming ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments